Here's a number that might surprise you: the DNA and RNA synthesis market is expected to explode from $21.4 billion in 2024 to $67.7 billion by 2030. That's a staggering 21.2% annual growth rate that reflects something profound happening in biotechnology.
This isn't just about lab equipment getting better. We're witnessing the convergence of multiple healthcare crises and technological breakthroughs. The growing need for early cancer detection is driving massive investment in genomic tools, while the rise of infectious diseases has made rapid genetic analysis essential. Meanwhile, personalized medicine is shifting from concept to clinical reality, with genome editing moving beyond research into actual patient treatment.
The technology landscape is evolving just as rapidly. Long-read sequencing and third-generation sequencing are solving problems that stumped scientists for decades, while CRISPR-based diagnostics are opening entirely new therapeutic pathways. Companies like Illumina and Thermo Fisher Scientific are racing alongside newer players like Oxford Nanopore Technologies and CRISPR Therapeutics to capture market share.
North America leads with 43.5% of the global market, but the real story is how next-generation sequencing technology is democratizing access to genetic analysis worldwide. What once required massive institutional resources is becoming accessible to smaller research facilities and clinical labs.
The challenges are real—sequencing instruments remain expensive, regulatory pathways are still evolving, and data management presents ongoing headaches. But the momentum is undeniable.
Want the full picture? Download the free overview of our report 2025 DNA and RNA Synthesis Research Review for detailed market forecasts and technology insights.
